Luminor Capital

Luminor Capital is a private equity group headquartered in Singapore, founded in 2008. The firm focuses on creating value and achieving investment returns by investing in high-growth sectors such as healthcare, resources, consumer, lifestyle, and infrastructure. With offices in Singapore and Beijing, Luminor Capital targets the Asia-Pacific region, where favorable economic conditions and entrepreneurial activity provide attractive business opportunities. The team's core expertise and competence guide their investment strategies, enabling them to capitalize on rewarding projects in this dynamic market.

Foo Fatt Kah

Co-Founder and Managing Director

5 past transactions

Capital C Corporation

Pre Seed Round in 2022
Capital C Corporation is a financial services provider based in Singapore that focuses on serving under-served communities. The company leverages fintech and emerging technologies to offer a diverse array of financial solutions, including individual loans, business loans, and auto financing. By employing a unique credit scoring methodology, Capital C Corporation aims to deliver accessible and affordable credit to both individuals and businesses, helping them unlock their potential and achieve their financial goals.

PT Adiwisista Finansial Teknologi

Series A in 2021
PT Adiwisista Finansial Teknologi operates in the financial services industry, focusing on leveraging technology to offer innovative solutions. Established in 2018, the company has grown to employ around 50 individuals dedicated to enhancing financial accessibility and efficiency. It has engaged in strategic partnerships, such as with Salvatore Financial for securities issuance and with Bank SMBC Indonesia for loan channeling. It oversees Danai.id, a platform under its umbrella, which has secured operational licensing from Indonesia's Financial Services Authority (OJK). The company's commitment to integrating technology with financial services is evident in its efforts to streamline processes and offer financial products that cater to the evolving needs of its clients.

ayondo

Series C in 2015
ayondo Ltd. is a financial technology company based in Singapore, founded in 2014, that specializes in brokerage and social trading services. With a focus on connecting traders and fostering a community, ayondo provides a platform that enables real-time signal execution, catering to self-directed investors, trading strategy providers, and followers. The company emphasizes transparency, low fees, and efficiency in its services, which are designed to enhance the trading experience. Additionally, ayondo offers tailored solutions for asset managers in the institutional sector and operates a franchise system to extend its reach globally.

ayondo

Series C in 2014
ayondo Ltd. is a financial technology company based in Singapore, founded in 2014, that specializes in brokerage and social trading services. With a focus on connecting traders and fostering a community, ayondo provides a platform that enables real-time signal execution, catering to self-directed investors, trading strategy providers, and followers. The company emphasizes transparency, low fees, and efficiency in its services, which are designed to enhance the trading experience. Additionally, ayondo offers tailored solutions for asset managers in the institutional sector and operates a franchise system to extend its reach globally.

TriReme Medical

Series E in 2012
TriReme Medical, Inc. is a privately held medical device company located in Pleasanton, California, established in 2005. The company focuses on the development and manufacturing of innovative stent technologies aimed at treating coronary artery disease, particularly in complex areas such as bifurcations. TriReme Medical specializes in advanced therapeutic technology systems for both coronary and peripheral vascular diseases. Its next-generation percutaneous devices, including novel balloon and stent therapies, address significant clinical needs in these markets, offering physicians differentiated tools to enhance patient outcomes in challenging vascular interventions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.